Aurinia to Participate in Upcoming Investor Conferences
VICTORIA, British Columbia--(BUSINESS WIRE)--Sep 19, 2018--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
The presentations will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of each presentation will also be archived on the site following the event.
Monday, October 1, 2018, Aurinia will present at the Cantor Fitzgerald 4th Annual Healthcare Conference in New York City at 8:55am ET.
Tuesday, October 2, 2018, Aurinia will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York City at 3:30pm ET.
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
We seek safe harbor.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005725/en/
CONTACT: Aurinia Pharmaceuticals Inc.
VP, Corporate & Public Affairs
Christopher Hippolyte, 212-364-0458
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Aurinia Pharmaceuticals Inc.
Copyright Business Wire 2018.
PUB: 09/19/2018 04:01 PM/DISC: 09/19/2018 04:01 PM